1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Lilly Preps Abemaciclib To Take On Ibrance; Differentiation Still A Question

 
• By Jessica Merrill

The CDK4/6 inhibitor showed progression-free survival in patients with breast cancer in an interim analysis, and Lilly plans to begin global regulatory submissions for the drug in the second quarter.

Breast Cancer Awareness: Microscopic image (photomicrograph) of core biopsy for infiltrating (invasive) ductal carcinoma, detected by screening mammogram. H & E stain.

Eli Lilly & Co.'s efforts to take on rivals Pfizer Inc. and Novartis AG in the lucrative cyclin-dependent kinase (CDK) 4/6 inhibitor space for advanced breast cancer have gotten another positive boost.

The company announced positive preliminary efficacy data from an interim analysis of the MONARCH 3 trial, showing a statistically significant improvement in progression-free survival in patients treated with abemaciclib in combination with an aromatase inhibitor, the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.